Ability of Lactobacillus plantarum LS/07 to modify intestinal enzymes activity in chronic diseases prevention.

The ability of probiotic strain Lactobacillus plantarum LS/07 to modify the activity of intestinal bacterial enzymes - ß-glucuronidase (ß-GLUCUR), ß-galactosidase (ß-GAL), and ß-glucosidase (ß-GLU) in prevention of chronic diseases - cancer, atherosclerosis and dysbiosis was investigated. The male Sprague-Dawley rats were randomly divided into 12 experimental groups: controls groups - C (control), AT (atherosclerotic), CC (carcinogenic), dysbiotic groups - each group in combination with antibiotics (ATB), probiotics groups - in combinatioan with probiotic (PRO) alone, and each group with combination of antibiotic and probiotic (ATB+PRO). In the control group the ß-glucuronidase activity did not change throughout the experiment. High fat diet in atherosclerotic group significantly increased the activity of ß-glucuronidase (P<0.001) and ß-glucosidase (P<0.01). Azoxymethane application in carcinogenic group significantly increased ß-glucuronidase (P<0.01), but reduced ß-glucosidase (P<0.01) activity. Daily application of probiotics alone and in combination with antibiotic increased ß-galactosidase, of ß-glucosidase, and decreased ß-glucuronidase activity. In control antibiotic group we observed significant increase in ß-glucuronidase (P<0.05) and decreased ß-glucosidase (P<0.01) activity which can be caused by the change of microflora in favor of coliform bacteria. These findings indicate the positive effects of probiotic Lactobacillus plantarum LS/07 and suggest its use in disease prevention in human medicine and some animal species.

Effect of Ivabradine on Endothelial Function in Patients with Stable Angina Pectoris: Assessment with the Endo-PAT 2000 Device.

INTRODUCTION: Ivabradine has opened up new possibilities for treating stable angina and chronic heart failure by lowering heart rate. Ivabradine lowers heart rate by selectively inhibiting the I f current in the sinoatrial node. This study aimed to determine whether the decrease in heart rate achieved with ivabradine was accompanied by hemodynamic changes that might lead to an enhancement of endothelial function. METHODS: Thirty patients with stable angina pectoris were included in the study. Ivabradine (5 mg bid) was added to the recommended standard treatment. Endothelial function was assessed at baseline and after 3 months of ivabradine therapy, with an Endo-PAT 2000 device (Itamar Medical, Israel). This device was recently developed for the noninvasive assessment for endothelial dysfunction. We evaluated reactive hyperemia index (RHI), which reflects endothelial function, and augmentation index (AI), which provides an indication of arterial stiffness. RESULTS: The study population consisted of 25 (83.3%) men and five (16.7%) women. The mean age of the patients was 65.4 ± 6.7 years. Twenty-eight (93.3%) patients had a history of myocardial infarction (ST-segment elevation myocardial infarction or non-ST-segment elevation myocardial infarction), 23 (76.6%) had undergone revascularization (percutaneous coronary intervention or coronary artery bypass graft), 16 (53.3%) had type 2 diabetes mellitus, and 29 (96.6%) had arterial hypertension. The mean resting heart rate decreased significantly, from 77 ± 7 bpm at the start of the study to 65 ± 6 bpm after treatment (P < 0.0001). Endothelial function was found to have improved significantly after 3 months of ivabradine therapy. Mean RHI before treatment was 1.54 ± 0.30, suggesting probable endothelial dysfunction, whereas mean RHI at the end of the study was 1.83 ± 0.36 (P < 0.0001). AI also improved significantly on treatment, from 21 ± 20% to 10 ± 21% (P < 0.0001). CONCLUSION: The addition of ivabradine to the treatment regimen of patients with stable angina pectoris both lowered heart rate and improved endothelial function. However, broader, randomized, double-blind, placebo-controlled clinical trials are required to confirm these findings.

Red cell antioxidant enzymes and prognostic indexes in patients with burns.

Red cell superoxide dismutase (SOD), glutathione peroxidase (GPX) and catalase (CAT) were measured in 66 burned patients (57 men, 9 women, age 16-78 years). BSAB varied from 15 to 93% and ABSI from 3 to 14 points. In the first week after injury the activity of SOD was significantly decreased as compared with the activity of the enzymes in the control group and was also below the reference values. Later the activity of SOD increased up to the normal range. The activity of CAT followed a similar pattern but the differences were not significant. No significant changes in red cell GPX were found during the monitored period. We did not find any significant association between the antioxidant enzyme activities and the markers of burns severity. On the other side there was a significant indirect association between the change of SOD activity (calculated as a difference between the first week values after the injury and the activities measured later) and BSAB.